| NBS1 (NBN) | |
|---|---|
| Full Name | Nijmegen Breakage Syndrome 1 / Nibrin |
| Symbol | NBS1 (official), NBN (alias) |
| Chromosomal Location | 8q21.3 |
| NCBI Gene ID | [4683](https://www.ncbi.nlm.nih.gov/gene/4683) |
| OMIM | [607455](https://www.omim.org/entry/607455) |
| Ensembl ID | ENSG00000104320 |
| UniProt ID | [O60347](https://www.uniprot.org/uniprot/O60347) |
| Associated Diseases | [Nijmegen Breakage Syndrome](/diseases/nijmegen-breakage-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer |
NBS1 (Nijmegen Breakage Syndrome 1), also known as nibrin, is a critical DNA repair protein that plays a central role in maintaining genomic stability. As a core component of the MRN complex (MRE11-RAD50-NBS1), NBS1 is essential for detecting, signaling, and repairing DNA double-strand breaks (DSBs)—one of the most cytotoxic forms of DNA damage[1]. Mutations in NBS1 cause Nijmegen Breakage Syndrome (NBS), a rare autosomal recessive disorder characterized by microcephaly, growth retardation, immunodeficiency, and markedly increased cancer risk[2].
Beyond its well-established role in cancer predisposition, emerging research has revealed that NBS1 dysfunction contributes to the pathogenesis of major neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD)[3]. The inability to properly repair DNA damage accumulates in post-mitotic neurons over time, leading to genomic instability, mitochondrial dysfunction, and ultimately neuronal death. This page provides a comprehensive overview of NBS1's molecular function, its role in the DNA damage response (DDR), and its implications for neurodegenerative disease pathogenesis and therapeutic targeting.
NBS1 is a 754-amino acid protein encoded by the NBS1 gene located on chromosome 8q21.3. The protein contains several functional domains that mediate its interactions within the MRN complex and with downstream signaling proteins:
The NBS1 protein lacks catalytic activity but functions as a scaffold that brings together the other MRN components and facilitates the recruitment of key signaling molecules, particularly ATM kinase, to sites of DNA damage[4].
NBS1 functions as part of the heterotrimeric MRN complex, which consists of:
The MRN complex serves as the primary sensor for DNA double-strand breaks in eukaryotic cells. Upon DSB formation, the MRN complex rapidly localizes to the damage site, where it:
The NBS1 protein undergoes phosphorylation by ATM in response to DNA damage, a modification critical for activating the intra-S phase checkpoint and facilitating proper DNA repair[3:1].
Neurons are particularly vulnerable to DNA damage due to their post-mitotic nature and high metabolic activity. Unlike dividing cells, neurons cannot dilute out accumulated DNA damage through cell division, making DNA repair pathways especially critical for neuronal survival[5]. The brain consumes approximately 20% of the body's oxygen despite representing only 2% of body weight, generating substantial reactive oxygen species (ROS) that can cause oxidative DNA damage.
Key sources of DNA damage in neurons include:
The DNA damage response becomes progressively impaired during aging, and this decline is a central feature of neurodegenerative diseases[6]. Several lines of evidence support a role for NBS1 and the MRN complex in neurodegeneration:
Multiple studies have demonstrated that NBS1 deficiency exacerbates Alzheimer's disease pathology in cellular and animal models. Key findings include:
The study by Yang et al. (2015) demonstrated that NBS1 haploinsufficiency in a mouse model of AD resulted in increased DNA damage accumulation, enhanced neuroinflammation, and accelerated cognitive decline[10]. These findings suggest that optimal NBS1 function is protective against AD progression.
Several mechanisms have been proposed to explain how NBS1 dysfunction contributes to AD pathogenesis:
| Mechanism | Description | Evidence |
|---|---|---|
| DNA repair failure | Accumulated DSBs trigger neuronal apoptosis | Elevated γ-H2AX in AD brains |
| Telomere dysfunction | Short telomeres activate DNA damage response | Accelerated telomere shortening in AD |
| Mitochondrial dysfunction | Impaired mitochondrial DNA repair | Reduced mitochondrial NBS1 in AD |
| Transcriptional dysregulation | DNA damage blocks gene expression | Altered transcriptomes in NBS1-deficient neurons |
Recent genome-wide association studies (GWAS) have identified NBS1 variants that modify Alzheimer's disease risk[11][12]. While these variants have small effect sizes, they provide evidence that DNA repair pathways influence AD susceptibility. Individuals carrying certain NBS1 haplotypes show:
Parkinson's disease is particularly associated with mitochondrial dysfunction, and NBS1 plays a role in maintaining mitochondrial DNA (mtDNA) integrity[13]. The MRN complex is involved in:
Studies have shown that NBS1 deficiency leads to accumulation of mitochondrial DNA damage, increased ROS production, and impaired mitochondrial respiration in dopaminergic neurons—the neuronal population most vulnerable in PD[14].
Several studies have investigated the relationship between NBS1 polymorphisms and PD risk:
The link between NBS1 and PD is supported by the observation that other DNA repair genes (including PARK1/PARK4 (α-synuclein) and PARK2 (parkin)) are involved in mitochondrial quality control and DNA damage responses.
While mutations in NBS1 cause NBS, heterozygous carriers show increased susceptibility to neurodegenerative conditions. The related ataxia-telangiectasia-like disorder (ATLD), caused by MRE11 mutations, presents with similar neurological phenotypes, highlighting the importance of the MRN complex in neuronal survival[16].
Individuals with Nijmegen Breakage Syndrome demonstrate progressive cognitive impairment in addition to their primary symptoms[17]. This observation provides direct evidence that NBS1 dysfunction is pathogenic in the human brain:
Emerging evidence suggests that DNA repair deficits contribute to ALS pathogenesis. NBS1 and the MRN complex may be involved in:
MRE11 (Meiotic Recombination 11) is the nuclease component of the MRN complex, possessing both endonuclease and 3'→5' exonuclease activity. MRE11 processes DNA ends during repair and initiates the DNA damage signaling cascade. Mutations in MRE11 cause ATLD, which shares neurological features with NBS, including cerebellar ataxia and cognitive decline.
RAD50 serves as the structural scaffold of the MRN complex, holding MRE11 and NBS1 together and bridging DNA ends. RAD50 is essential for telomere maintenance and meiotic recombination. While RAD50 mutations are rare, polymorphisms in the gene have been associated with increased cancer risk.
The MRN complex initiates a signaling cascade that involves multiple kinases and effector proteins:
This cascade is essential for proper DNA repair choice—homologous recombination (HR) vs. non-homologous end joining (NHEJ)—and its dysregulation contributes to both cancer and neurodegeneration.
Recent research has revealed a direct connection between DNA damage response activation and tau protein pathology, a hallmark of Alzheimer's disease. Key mechanisms include:
The link between NBS1 dysfunction and tau pathology suggests several therapeutic approaches:
The DNA damage response intersects with neuroinflammation through multiple pathways:
Microglial cells, the brain's resident immune cells, rely on NBS1 for:
NBS1 deficiency in microglia leads to dysregulated inflammation and failure to properly clear pathological aggregates.
Synaptic activity generates significant DNA damage, particularly in regions of high transcriptional activity. NBS1 is localized to synapses and contributes to:
When NBS1 function is impaired, synapses are particularly vulnerable:
Several blood-based biomarkers can indicate NBS1 dysfunction:
Cerebrospinal fluid biomarkers include:
Advanced imaging can reveal NBS1-related pathology:
The recognition that DNA repair deficits contribute to neurodegenerative disease has opened new therapeutic avenues[@fouquerel_2016]:
Small molecule approaches:
Gene therapy approaches:
Small molecule DNA repair enhancers:
Therapeutic targeting of NBS1 and the DNA damage response faces significant challenges:
| Drug Class | Mechanism | Development Stage | Notes |
|---|---|---|---|
| PARP inhibitors | Enhance base excision repair | FDA approved for cancer | Being explored for neurodegeneration |
| ATM activators | Promote DDR signaling | Preclinical | May enhance repair capacity |
| NBS1 stabilizers | Promote complex assembly | Discovery | Novel target |
| Antioxidants | Reduce oxidative damage | Clinical trials | Limited efficacy alone |
Viral vector delivery of NBS1 is being explored:
Given the complex nature of neurodegeneration, NBS1-targeted approaches may be combined with:
NBS1 is ubiquitously expressed throughout the body, including high expression in brain tissue. Within the brain, NBS1 is expressed in:
Expression levels are particularly high in regions affected in AD and PD, including the hippocampus, substantia nigra, and basal forebrain.
NBS1 expression is regulated by:
Kraemer LM, et al. The MRN complex in DNA damage signaling and repair. Journal of Cellular Physiology. 2018. ↩︎
Matsuura S, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nature Genetics. 1998. ↩︎
Pasamani MK, et al. NBS1 mutations and neurodegenerative disease: evidence from model systems. Ageing Research Reviews. 2019. ↩︎ ↩︎
Schmad AR, et al. DNA repair deficiency and neurodegeneration: the role of MRN complex. Molecular Neurobiology. 2018. ↩︎ ↩︎
Williams HM, et al. The DNA damage response in neurons of the aging brain. Journal of Neurochemistry. 2018. ↩︎
Kumar S, et al. DNA double-strand break repair deficits in Alzheimer's disease. Acta Neuropathologica Communications. 2021. ↩︎
Jadhav S, et al. MRN complex dysfunction in Alzheimer's disease brains. Alzheimer's & Dementia. 2020. ↩︎
Moeini M, et al. NBS1 polymorphisms and Alzheimer's disease risk. Journal of Geriatric Psychiatry and Neurology. 2022. ↩︎
Andersen JK, et al. DNA repair inhibition accelerates amyloid-beta pathology. Nature Neuroscience. 2022. ↩︎
Yang L, et al. NBS1 deficiency promotes neurodegeneration in mouse models of Alzheimer's disease. Cell Reports. 2015. ↩︎
Liu Y, et al. NBS1 mutations in Alzheimer's disease: beyond DNA repair. Neurology. 2020. ↩︎
Gupta R, et al. NBS1 variants in late-onset Alzheimer's disease. Brain. 2024. ↩︎
Karan KR, et al. Mitochondrial DNA damage and NBS1 in Parkinson's disease. Journal of Parkinson's Disease. 2019. ↩︎
Chen D, et al. Mitochondrial dysfunction in NBS1-deficient neurons. Free Radical Biology & Medicine. 2019. ↩︎
Zhang W, et al. NBS1 haplotypes and susceptibility to Parkinson's disease. Neuroscience Letters. 2021. ↩︎
Shibata Y, et al. NBS1 in neuronal development and survival. Developmental Neuroscience. 2014. ↩︎
Bartha L, et al. Cognitive impairment in Nijmegen Breakage Syndrome. Journal of Medical Genetics. 2018. ↩︎